XXVIIth International Workshop on Helicobacter and Microbiota in Inflammation and Cancer

Rome, Italy
September 11 - 13, 2014

FINAL PROGRAMME
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcoming Address</td>
<td>3</td>
</tr>
<tr>
<td>Awardees of the Marshall and Warren Medal</td>
<td>3</td>
</tr>
<tr>
<td>Patronage</td>
<td>4</td>
</tr>
<tr>
<td>Committees – Organisation</td>
<td>5</td>
</tr>
<tr>
<td>Workshops of the EHSG</td>
<td>5</td>
</tr>
<tr>
<td>Location Map</td>
<td>6</td>
</tr>
<tr>
<td>Programme at a Glance</td>
<td>7</td>
</tr>
<tr>
<td><strong>Scientific Programme</strong></td>
<td></td>
</tr>
<tr>
<td>- Thursday, September 11</td>
<td>10</td>
</tr>
<tr>
<td>- Friday, September 12</td>
<td>11</td>
</tr>
<tr>
<td>- Saturday, September 13</td>
<td>18</td>
</tr>
<tr>
<td><strong>Scientific Information, Poster Schedule</strong></td>
<td>23</td>
</tr>
<tr>
<td><strong>Company Sponsored Symposia</strong></td>
<td>25</td>
</tr>
<tr>
<td><strong>Acknowledgements</strong></td>
<td>25</td>
</tr>
<tr>
<td><strong>List of Exhibitors</strong></td>
<td>25</td>
</tr>
<tr>
<td><strong>General Information</strong></td>
<td>26</td>
</tr>
<tr>
<td><strong>Registration Details</strong></td>
<td>28</td>
</tr>
<tr>
<td><strong>Networking Events</strong></td>
<td>28</td>
</tr>
</tbody>
</table>
Dear colleagues and friends,

Thank you for being here in Rome in occasion of the XXVIIth International Workshop on Helicobacter and Microbiota in Inflammation and Cancer.

14 years after the 2000’s event we are back in the eternal city to learn all the scientific discoveries on the role of Helicobacter in inflammatory and neoplastic diseases. In particular, this meeting will focus on the role of Helicobacter and other components of the microbiota in health and pathological conditions. In facts, the therapeutical opportunities determined by gut microbiota modulation are among the most challenging area of interest not only for gastroenterology but for all medicine and the incredible novelties presented in the EAGEN postgraduate course on microbiota transplantation that preceded the EHSG meeting are a perfect example of this.

In these 3 days new epidemiological aspects, novel pathogenic mechanism of the host-helicobacter interaction and up to dated diagnostic and therapeutical guidelines will be covered by the world leading scientists.

Thank you for being here, my friends, I hope that you can have a fantastic and fruitful EHSG meeting and enjoy the magic Rome, an ancient romantic city projected in the future, ready to show you all its beauties

Welcome to Rome!
Benvenuti a Roma!

Giovanni Gasbarrini
President of the European Helicobacter Study Group
PATRONAGE

UNDER THE HIGH PATRONAGE OF

The President of the Italian Republic

UNDER THE AUSPICES OF:

- Italian Ministry on Health
- Roma Capitale
- SIGE Italian Society of Gastroenterology

CME ACCREDITATION

The European Helicobacter Study Group is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The XXVIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer is designated for a maximum of 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
COMMITTEES – ORGANISATION

Local Organizing Committee

President
Giovanni Gasbarrini, Rome

Members
B. Annibale, Rome
F. Bazzoli, Bologna
G. Cammarota, Rome
F. Di Mario, Treviso
M.P. Dore, Sassari
R. Francavilla, Bari
F. Franceschi, Rome
A. Franzè, Rome
E. Ierardi, Foggia

Coordinator:
Antonio Gasbarrini, Rome

European Helicobacter Study Group (EHSG)

President
Giovanni Gasbarrini, Italy

Members
Leif P. Andersen, Denmark
Anthony Axon, United Kingdom
Lars Engstrand, Sweden
Bram Flahou, Belgium
Javier P. Gisbert, Spain
Ernst Kuipers, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Colm A. O’Morain, Ireland
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece

Emeritus Members
Michel A.L. Deltenre, Belgium
Pierre Michetti, Switzerland
José M. Pajares Garcia, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Corresponding Fellows
Niyaz Ahmed, India
Luis G. Vaz Coehlo, Brazil
Toshibo Fujioka, Japan
Hyun Chae Jung, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Shu Dong Xiao, China

Emeritus Members
Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Honorary Members
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Organising Offices

Core Agency
Vienna Medical Academy
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 0
Fax: +43 1 407 82 74
ehsg2014@medacad.org

Technical Exhibition
MAW
Freyung 6
A-1010 Vienna, Austria
Phone: +43 1 536 63 15
Fax: +43 1 535 60 16
maw@media.co.at

Local Agency
Studio ega srl
v.lle Tiziano 19
00196 Rome, Italy
Phone: +39 0632812327,
Fax: +39 063240143
ehsg2014@ega.it

Workshops of the EHSG

- Bordeaux (1988)
- Ulm (1989)
- Toledo (1990)
- Bologna (1991)
- Dublin (1992)
- Brussels (1993)
- Houston (1994)
- Copenhagen (1996)
- Lisbon (1997)
- Budapest (1998)
- Helsinki (1999)
- Rome (2000)
- Strasbourg (2001)
- Athens (2002)
- Vienna (2004)
- Copenhagen (2005)
- Wroclaw (2006)
- Istanbul (2007)
- Riga (2008)
- Porto (2009)
- Rotterdam (2010)
- Dublin (2011)
- Ljubljana (2012)
- Madrid (2013)
- Rome (2014)

Next Workshop: Nicosia, Cyprus, September 24-26, 2015

www.helicobacter.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30 – 16.00 hrs</td>
<td>Laurea Honoris Causa Nobel Prize Barry Marshall by the Catholic University Auditorium by Franco Anelli, Chancellor of the Catholic University</td>
</tr>
<tr>
<td>16.00 – 17.00 hrs</td>
<td>Honorary lecture Auditorium</td>
</tr>
<tr>
<td></td>
<td>The discovery of <em>Helicobacter pylori</em> as cause of peptic ulcer and the consequences on the clinical practice. <em>Barry Marshall, Perth, Australia</em></td>
</tr>
<tr>
<td>17.00 – 17.30 hrs</td>
<td>Welcome Addresses and Introductory remarks Auditorium</td>
</tr>
<tr>
<td></td>
<td>Giovanni Gasbarrini, President of the EHSG Ignazio Marino, Mayor of Rome Authorities</td>
</tr>
<tr>
<td>17.30 hrs</td>
<td>Networking Mixer at the conference venue Foyer or outside, weather permitting</td>
</tr>
</tbody>
</table>
PROGRAMME AT A GLANCE

Friday, September 12, 2014

08.30 – 10.00 hrs
Symposium: Only H. pylori in the stomach?
Auditorium
- Impact of H. pylori on gastric microbiota and after treatment, Lars Engstrand, Stockholm, Sweden
- Gastric microbiota during prolonged acid-suppressant therapy, Giovanni Brandi, Bologna, Italy
- Survival in hostile territory: Gastric microbiota composition & gastric disease, S. Suerbaum, Hanover, Germany
- Gastritis in preneoplastic evolution, Maria Varbanova, Magdeburg, Germany
- Gastric microbiota and bacterial metabolism in gastric cancer, Ceu Figueiredo, Porto, Portugal

10.00 – 10.30 hrs
State of the Art Lecture
Auditorium
Kyoto Consensus on gastritis, Ken Sugano, Japan

10.30–11.00 hrs
Coffee break

11.00–12.30 hrs
Parallel Workshops 1 – 2

W1 Microbiology
Auditorium

W2 Therapy
Sala Italia

12.30 – 13.30 hrs
Company Sponsored Symposium
Auditorium

13.30–14.30 hrs
Lunch

13.30–14.30 hrs
Poster Rounds

- Group 1
  1. Microbiology
  2. Molecular genetics and genomics
  3. Virulence factors and pathogenesis
  13. Drug resistance

- Group 2
  11. Clinical trials and novel treatments
  15. Probiotics

14.30–16.00 hrs
Symposium: Host-bacterial interactions
Auditorium
- Human and H. pylori interaction in gastric carcinogenesis, Keith Wilson, Nashville, TN, USA
- Role of Helicobacter-gammaGT in gastric pathogenesis, Bram Flahou, Gent, Belgium
- H. pylori and gastric mucosa re-programming, Masanori Hatakeyama, Tokyo, Japan
- Gastric mucosa modeling factors in H. pylori infection, Jan Bornschein, Magdeburg, Germany

16.00–16.30 hrs
Coffee break

16.30–18.00 hrs
Parallel Workshops 3 – 4

W3 Epidemiology and Paediatrics
Auditorium

W4 Pathology
Sala Italia

20.00 hrs
EHSG Networking Dinner
(Ticket required at entrance - event is booked out)
PROGRAMME AT A GLANCE

Saturday, September 13, 2014

08.30–10.00 hrs
Symposium: Extragastric manifestations of *H. pylori* infection - Association or causation?
*Auditorium*
- Cardiovascular diseases, Francesco Franceschi, Rome, Italy
- Hematology, Bruno Annibale, Rome, Italy
- Nutrition, obesity and metabolism, Antonio Gasbarrini, Rome, Italy
- Mind Altering Microbes, Sylvia Dobbs, London, UK

10.00 – 10.30 hrs
State of the Art Lecture
*Auditorium*
- Bariatric surgery and gastrointestinal microbiota, Lars Lundell, Stockholm, Sweden

10.30–11.00 hrs
Coffee break

11.00–12.30 hrs
Parallel Workshops 5 – 6
- **W5 Gastric Cancer**
  *Auditorium*
- **W6 Extradigestive and Others**
  *Sala Italia*

12.30 – 13.30 hrs
Company Sponsored Symposium
*Auditorium*
- Lunch

13.30–14.30 hrs
**Poster Rounds**
- **Group 3**
  4. Epidemiology and transmission
  9. Paediatric issues
  10. Diagnosis
- **Group 4**
  5. Inflammation and host response
  6. Pathology and pathophysiology
  7. Preneoplastic and neoplastic diseases
- **Group 5**
  18. *H. pylori* and Gastric Cancer
- **Group 6**
  8. Oesophageal and extradigestive diseases
  12. NSAIDs, COXIBs, ASA and *H. pylori* infection
  16. Other Helicobacters
  17. Hepatobiliary Diseases

14.30–16.00 hrs
Symposium: Prevention of gastric cancer by *H. pylori* eradication
*Auditorium*
- Report of the IARC Working Group Meeting on *H. pylori* eradication for gastric cancer prevention, R. Herrero, Lyon, France
- Cost-effectiveness of test and treat strategy for gastric cancer prevention, Paul Moayyedi, Hamilton, ON, Canada
- Prevention of gastric cancer besides *H. pylori* eradication in Korea, Soo Heon Park, Seoul, Korea
- Public health perspectives, Ruggero de Maria, Rome, Italy

16.00–16.30 hrs
Coffee break

16.30–18.00 hrs
**Debate: Best *H. pylori* eradicating schemes**
*Auditorium*
- Back to the future: Bismuth, David Graham, Houston, TX, USA
- Non-bismuth quadruple therapies, Javier P. Gisbert, Madrid, Spain
- Personalised treatment, Takahisa Furuta, Hamamatsu, Japan
- Back from the future: Vaccine, Antonello Covacci, Siena, Italy

18.00–18.30 hrs
**Awarding of the Marshall and Warren Medal**
**Presentation of the next meeting Nicosia, Cyprus**
**Closing remarks**
*Auditorium*

www.helicobacter.org
PROGRAMME THURSDAY, SEPTEMBER 11

15.30 - 16.00 hrs
Laurea Honoris Causa Nobel Prize Barry Marshall by the Catholic University
Room: Auditorium
presented by Franco Anelli, Chancellor of the Catholic University

16.00 - 17.00 hrs
Honorary lecture
Room: Auditorium
The discovery of Helicobacter pylori as cause of peptic ulcer and the consequences on the clinical practice.
Barry Marshall, Perth, Australia

17.00 - 17.30 hrs
Welcome Addresses and Introductory remarks
Room: Auditorium
Giovanni Gasbarrini, President of the XXVII EHSG Workshop
Ignazio Marino, Mayor of Rome
Authorities

17.30 hrs
Networking Mixer in the foyer or outside weather permitting
08.30 – 10.00 hrs  Symposium: Only *H. pylori* in the stomach?
*Auditorium*

Chair: E. Ierardi, Italy
J. Machado, Portugal

Speaking Time: 17’+3’ (except *: 12’+3’ and **: 8’+2’)

**Impact of *H. pylori* on gastric microbiota and after treatment**
*Lars Engstrand, Stockholm, Sweden*

**Gastric microbiota during prolonged acid-suppressant therapy**
*Giovanni Brandi, Bologna, Italy*

**Survival in hostile territory: Gastric microbiota composition & gastric disease***
*S. Suerbaum, Hanover, Germany*

**Gastritis in preneoplastic evolution** **
*Maria Varbanova, Magdeburg, Germany*

**Gastric microbiota and bacterial metabolism in gastric cancer**
*Ceau Figueiredo, Porto, Portugal*

---

10.00 – 10.30 hrs  State of the Art Lecture
*Auditorium*

Chair: D. Graham, United States
C. Scarpignato, Italy

Speaking Time: 20’+5’

**Kyoto Consensus on gastritis**
*Ken Sugano, Japan*

---

10.30 – 11.00 hrs  Coffee break
11.00 – 12.30 hrs  Workshop 1. Microbiology

**Room:** Sala Italia

**Chair:** F. Mégraud, France  
M. Sanguinetti, Italy

**Speaking time:** 12'+3'

**W1.1** Methylome dynamics in *H. pylori*
I. Kobayashi;  
*University of Tokyo, Tokyo, Japan.*

**W1.2** Where did the *Helicobacter pylori* prophages came from?
F. F. Vale¹,², J. Vadiivelu¹, S. Indran⁴, F. Mégraud¹,², P. Lehours¹,²;  
¹Université de Bordeaux, Laboratoire de Bactériologie, Bordeaux, France, ²INSERM U853, Bordeaux, France, ³UM Marshall Centre and Dept of Medical Microbiology, University of Malaya, Lembah Pantai, 50490 Kuala Lumpur, Malaysia, ⁴UM Marshall Centre and Dept of Medical Microbiology, University of Malaya, Lembah Pantai, Malaysia, 50490 Kuala Lumpur, Malaysia.

**W1.3** Comparative genome analysis of two *Helicobacter pylori* strains isolated from the same patient
V. G. Zhukovitsky¹, A. V. Mardanov², A. V. Beletsky², N. V. Ravin³;  
¹Botkin Hospital, Moscow, Russian Federation, ²“Bioengineering” Centre of the Russian Academy of Science, Moscow, Russian Federation.

**W1.4** miR-155 expression in *Helicobacter pylori* infected gastric mucosa
W. Schirrmeister¹, C. Langner¹, T. Wex², A. Link¹, P. Malfertheiner¹;  
¹Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany, ²Medical Laboratory for Clinical Chemistry, Microbiology, and Infectious Diseases, Department Molecular Genetics, Magdeburg, Germany.

**W1.5** Proton pump inhibitors alter gastric microbiota composition in subjects with upper gastrointestinal symptoms: preliminary metagenomics analysis
F. Paroni¹, G. Cammarota², F. Bugli², S. Bibbò², G. Ianiro³, M. Iacono⁴, E. D. Capoluongo⁵, F. Scaldati⁶, A. Gasbarini⁶, M. Sanguinetti⁶, L. Masucci⁶;  
¹Institute of Microbiology, Catholic University School of Medicine, Rome, Italy, ²Division of Internal Medicine and Gastroenterology, Catholic University School of Medicine, Rome, Italy, ³Institute of Microbiology, Catholic University School of Medicine, Rome, Italy, ⁴Roche Diagnostics, Rome, Italy, ⁵Laboratory of Clinical Molecular Biology, Catholic University School of Medicine, Rome, Italy, ⁶Institute of Microbiology, Catholic University School of Medicine, Rome, Italy.

**W1.6** High prevalence of multi-drug resistance in *H. pylori* isolates from 1001 naïve patients
V. Castelli¹, N. Vakil², G. Fiorini³, I. Saracino¹, C. Zaccaro¹, C. Ricci³, A. Zullo⁴, L. Gatta⁴, B. Vaira⁴;  
¹Department of Medical and Surgical Sciences, Bologna, Italy, ²School of Medicine & Public Health, University of Wisconsin, WI, United States, ³Gastroenterology Unit, University of Brescia, Brescia, Italy, ⁴Department of Gastroenterology and Digestive Endoscopy, “Nuovo Regina Margherita” Hospital, Italy, ⁵Gastroenterology and Digestive Endoscopy Unit, Versilia Hospital, Lido di Camaiore, Italy.
11.00 – 12.30 hrs  Workshop 2. Therapy  Auditorium

Chair:  C. O’Morain, Ireland  
D. Vaira, Italy

Speaking time:  12'+3'

W2.1  Pan-European Registry on H. pylori Management (Hp-EuReg): Interim Analysis of 5,792 Patients


1Hospital de la Princesa, IP and CIBEREHD, Madrid, Spain, 2U. Sacro Cuore, Rome, Italy, 3AM DC Rogaska, Ljubljana, Slovenia, 4Central Hospital, Østfold, Norway, 5Clinical Sci. Centre, Moscow, Russian Federation, 6Medical University, Kyiv, Ukraine, 7Hospital Henry Dunant, Athens, Greece, 8U. of Health Sciences, Kaunas, Lithuania, 9University of Latvia, Riga, Latvia, 10Clinical Hospital, Zagreb, Croatia, 11IPATIMUP, Porto, Portugal, 12Medical University of Sofia, Sofia, Bulgaria, 13Medical C. Postgraduate Education, Warsaw, Poland, 14Dokuz Eylul University, Izmir, Turkey, 15Ferencvaros Health Centre, Budapest, Hungary, 16University of Leeds, Leeds, United Kingdom, 17University Hospital Basel, Basel, Switzerland, 18Kege University Hospital, Kege, Denmark, 19CHU Charleroi, Charleroi, Belgium, 20CECH Timisoara, Timisoara, Romania, 21Erasmus Medisch Centrum, Rotterdam, Netherlands, 22Herttoniemi Hospital, Helsinki, Finland, 23Hopital Pellegrin, Bordeaux, France, 24Trinity College Dublin, Dublin, Ireland.

W2.2  A Newly developed potassium-competitive acid blocker, Vonoprazan vs. Lansoprazole in First-Line Triple Therapy with Amoxicillin, and Clarithromycin for H. pylori Eradication - Phase 3, Double-Blind Study-

K. Murakami1, Y. Sakurai2, M. Shiino3, N. Funao2, A. Nishimura2, M. Asaka3;

1Department of Gastroenterology Faculty of Medicine, Oita University, Oita, Japan, 2Takeda Pharmaceutical Company, Ltd., Osaka, Japan, 3Department of Cancer Preventive Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.

W2.3  A network meta-analysis of first-line H. pylori eradication regimens


1Hospital de La Princesa, IP and CIBEREhd, Madrid, Spain, 2Spanish Agency for Medicines and Health Products (AEMPS), Madrid, Spain, 3Spanish National Research Council (CSIC), Madrid, Spain.

W2.4  A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high clarithromycin resistance area


1Athens Medical, P. Faliron Hospital, P. Faliro, Athens, Greece, 2Alexandra General Hospital, Athens, Greece, 3Hellenic Pasteur Institute, Athens, Greece, 4Central Clinic of Athens, Athens, Greece, 5Athens Medical Amaroussion Hospital, Athens, Greece, 6Metropolitan Hospital, N. Faliro, Athens, Greece.

W2.5  Tailored versus bismuth quadruple versus concomitant therapy for the first-line treatment of Helicobacter pylori in Chinese patients: a multicentre, open-label, randomized control trial

L. Zhou1, Z. Song1, J. Zhang1, Q. Qian2, Y. Li3, P. Bai2, Y. Wang4, Y. Xue5;

1Peking University Third Hospital, Beijing, China, 2National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 3Peking Union Medical College Hospital, Beijing, China, 4Qilu Hospital of Shandong University, Jinan, China.

W2.6  Triple therapy, sequential therapy, and concomitant therapy for Helicobacter pylori infection in Korea: a multicenter, randomized controlled trial

J. Kim1, J. Kim1, B. Kim1, H. Kim1, B. Bang2, C. Kim2, T. Kim1, S. Hong2, J. Han3;

1The Catholic University of Korea, Incheon, Korea, 2Imha University, Incheon, Korea, 3The Catholic University of Korea, Bucheon, Korea, 4SoonChunHyang University, Bucheon, Korea.
### PROGRAMME FRIDAY, SEPTEMBER 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30 – 14.30 hrs</td>
<td>Poster Rounds</td>
<td></td>
</tr>
</tbody>
</table>

**The following posters will be discussed with the authors**

**Group 1:**

1. Microbiology  
2. Molecular genetics and genomics  
3. Virulence factors and pathogenesis  
13. Drug resistance

**Chairs:**

- P01.01 - P01.11: A. Covacci, Italy  
  A. Link, Germany
- P03.01 - P03.14: A. Covacci, Italy  
  A. Link, Germany
- P02.01 - P02.18: M. Genuardi, Italy  
  M. Hatakeyama, Japan
- P13.01 - P13.29: T. Furuta, Japan  
  V. Ojetti, Italy

**Group 2:**

11. Clinical trials and novel treatments  
15. Probiotics

**Chairs:**

- P11.01 - P11.23: F. Bazzoli, Italy  
  M. P. Dore, Italy
- P11.24 - P11.47: G. Potamitis, Cyprus  
  F. Franceschi, Italy
- P11.48 - P11.60 & P15.01 - P15.06: B. Tepes, Slovenia  
  A. Franzè, Italy
14.30 – 16.00 hrs  
**Symposium: Host-bacterial interactions**  
*Auditorium*

**Chair:**  
S. Suerbaum, Germany  
M. Romano, Italy

**Speaking Time:**  
17’+3’

**Human and *H. pylori* interaction in gastric carcinogenesis**  
*Keith Wilson, Nashville, TN, USA*

**Role of Helicobacter-gammaGT in gastric pathogenesis**  
*Bram Flahou, Gent, Belgium*

**H. pylori and gastric mucosa re-programming**  
*Masanori Hatakeyama, Tokyo, Japan*

**Gastric mucosa modeling factors in *H. pylori* infection**  
*Jan Bornschein, Magdeburg, Germany*

16.00 – 16.30 hrs  
**Coffee break**
16.30 – 18.00 hrs

Workshop 3. Epidemiology and Paediatrics

Room: Auditorium

Chair: T. Rokkas, Greece
M. Zagari, Italy

Speaking Time: 12'+3'

W3.1 Antimicrobial Resistance of *Helicobacter pylori* Isolates in Alaska Native Persons from 2000-2013: Results from the Alaska Sentinel Surveillance Project

M. G. Bruce¹, J. Morris¹, D. Bruden¹, A. Reasonover¹, D. Hurtburt¹, B. McMahon²;
¹Centers for Disease Control and Prevention, Anchorage, AK, United States, ²Alaska Native Tribal Health Consortium, Anchorage, AK, United States.

W3.2 The prevalence of *Helicobacter pylori* remains high in African-American and Hispanic veterans

T. H. Nguyen¹,², D. Ramsey¹,², D. Y. Graham¹,², S. Shiota¹,², Y. Shaib¹,², M. Velez¹,², R. Cole¹,², B. Anand¹,², M. Vela¹, H. B. El-Serag¹,²;
¹Baylor College of Medicine, Houston, TX, United States, ²Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX, United States.

W3.3 *H. pylori* infection rate is higher between the third and the fifth decade of life in patients from less-industrialized countries: a good opportunity for gastric cancer prevention?

F. Mangiola¹, F. Del Zompo¹, G. Vanella¹, G. D’Angelo¹, D. Feliciani¹, F. Beghella Bartoli¹, V. Tesori¹, T. A. Di Rienzo¹, L. R. Lopetuso¹, A. Tortora¹, M. C. Campanale¹, F. Scaldaferrri¹, M. Candelli¹, M. Gabrielli¹, V. Ojetti¹, E. Gaetani¹, G. B. Gasbarrini², A. Gasbarrini¹, F. Franceschi¹;
¹Policlinico A. Gemelli, Rome, Italy, ²Fondazione Ricerca in Medicina, Bologna, Italy.

W3.4 *H. pylori* infection with CagA-positive strains is associated with anaemia in infants and toddlers

D. M. M. Queiroz¹, L. L. C. Braga²,², S. L. Perry³, A. M. C. Rocha¹, G. A. Rocha¹, J. E. Crabtree³;
¹Universidade Federal de Minas Gerais/Faculdade de Medicina, Belo Horizonte, Brazil, ²Universidade Federal do Ceará, Fortaleza, Brazil, ³Leeds Institute of Molecular Medicine/University of Leeds, Leeds, United Kingdom.

W3.5 Evolution of *Helicobacter pylori* associated gastro-duodenal ulcers or erosions over the last 23 years: decline or steady state?

M. Burgard⁴, K. Kotliea⁴, J. Mekhael⁴, Y. Miendje-Deyi², C. De Prez², J. Vanderpas⁴, S. Cadranel⁴, P. Bontems¹;
¹Paediatric Gastroenterology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium, ²Microbiology department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium, ³Pathology department, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium, ⁴Scientific Institute of Public Health, Brussels, Belgium.

W3.6 Gas production during lactulose breath test is associated with *Helicobacter pylori* infection

Department of Internal Medicine, Policlinico A. Gemelli, Rome, Italy.

20.00 hrs

EHSG Networking Dinner (Ticket required - Event sold out)
16.30 – 18.00 hrs  Workshop 4. Pathology
Room: Sala Italia
Chair: K. Wilson, United States
M. Rugge, Italy
Speaking Time: 12’+3’

W4.1 Inflammatory response in neonatal thymectomized BALB/c mice infected by Helicobacter pylori strains.
A. Laur¹, D. Chrisment¹, V. Korolik², P. Floch¹, L. Chambonniere¹, L. Benejat¹, X. Gauthereau², A. Giese², D. Capellen¹, Y. Idrissi², P. Dubus³, A. Bandeira², F. Mégraud¹, P. Lehours¹;
¹University of Bordeaux, INSERM U853, Bordeaux, France, ²Institute for Glycomics, Microbial Glycobiology, Griffith University, Gold Coast, Australia, ³CIRID, UMR 5164, Bordeaux, France, ⁴University of Bordeaux, EA 2406, Bordeaux, France, ⁵Institut Pasteur, Unité Lymphopoïèse, INSERM U668, Paris, France.

W4.2 Helicobacter pylori activates C-type lectin, Mincle: yet another survival strategy?
S. Devi, N. Ahmed; Pathogen Biology Laboratory, Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, India.

W4.3 Helicobacter pylori growth is associated with altered iron homeostasis in AGS cells
S. E. Flores, A. S. Day, J. I. Keenan; University of Otago, Christchurch, New Zealand.

W4.4 Role of CagA-positive strains of H. pylori in acute myocardial infarction with ST-segment elevation
F. Franceschi, A. Tortora, M. Roberto, G. Niccoli, T. A. Di Rienzo, G. D’Angelo, F. Mangiola, F. Scaldaferri, L. R. Lopetuso, V. Gerardi, L. Laterza, V. Ojetti, F. Del Zompo, M. Candelli, M. Gabrielli, F. Crea, G. Gasbarrini, A. Gasbarrini; Catholic University of Rome, Rome, Italy.

W4.5 Primary Gastric Lymphoma Detected by Screening Upper Endoscopy in High Prevalence Area of Helicobacter pylori Infection
H. yang¹, C. Lee², L. Seon Hee³, J. Yang³, S. Kang³, M. Park³, S. Chung³, J. Im³, S. Kim³, J. Kim³;
¹Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea, ²Seoul National University Hospital Healthcare System, Seoul National University College of Medicine, Seoul, Korea.

W4.6 Serum pepsinogens for detection of fundic gastric atrophy in subjects with autoimmune thyroid disease
M. Venerito, M. Radünz, K. Reschke, P. Mertens, F. Di Mario, P. Malfertheiner; Otto-von-Guericke University, Magdeburg, Germany.

20.00 hrs  EHSG Networking Dinner (Ticket required - Event sold out)
08.30 – 10.00 hrs  Symposium: Extragastric manifestations of *H. pylori* infection - Association or causation?

*Room:* Auditorium

*Chair:* G. Cammarota, Italy
R. Landolfi, Italy

*Speaking Time:* 17’+3’

**Cardiovascular diseases**
*Francesco Franceschi, Rome, Italy*

**Hematology**
*Bruno Annibale, Rome, Italy*

**Nutrition, obesity and metabolism**
*Antonio Gasbarrini, Rome, Italy*

**Mind Altering Microbes**
*Sylvia Dobbs, London, UK*

10.00 – 10.30 hrs  State of the Art Lecture

*Room:* Auditorium

*Chair:* P. Malfertheiner, Germany
G. Gasbarrini, Italy

*Speaking Time:* 20’+5’

**Bariatric surgery and gastrointestinal microbiota**
*Lars Lundell, Stockholm, Sweden*

10.30 – 11.00 hrs  Coffee Break
**PROGRAMME SATURDAY, SEPTEMBER 13**

11.00 – 12.30 hrs  Workshop 5. Gastric Cancer  
**Room:** Auditorium

Chair: S.H. Park, Korea  
A. Zullo, Italy

Speaking Time: 12’+3’

**W5.1** The decreasing incidence of gastric MALT lymphoma and *Helicobacter pylori* treatment  
A. Savio, C. Zambelli, R. Rodello, P. Cesari, F. Rolli, F. Zorzi; Fondazione Poliambulanza, Brescia, Italy.

**W5.2** IL1B signaling leads to increased cell survival of gastric carcinoma cells  
C. Resende1,2, G. Regalo1, C. Durães1, W. Xiaogang2, C. Figueiredo1,3, J. C. Machado1;  
1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal,  
2Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Porto, Portugal,  
3Faculty of Medicine of the University of Porto, Porto, Portugal.

**W5.3** *Helicobacter pylori* infection and gastric mucin expression in first degree relatives of gastric cancer subjects  
D. Boltin, S. Morgenstern, M. Roth, Z. Levi, Y. Niv; Rabin Medical Center, Petah Tikva, Israel.

**W5.4** Pattern recognition receptors in *Helicobacter pylori*-related gastric cancer  
N. Castaño Rodríguez1, N. Kaakoush1, G. Khean-Lee2, F. Kwong Ming3, H. Mitchell4;  
1The University of New South Wales, Sydney, Australia, 2University of Malaya, Kuala Lumpur, Malaysia,  
3Changi General Hospital, Singapore, Singapore.

**W5.5** Expression of aldehyde dehydrogenase defines cancer stem cell population in gastric carcinoma  
P. H. Nguyen1,2, L. Chambonnier1,2, F. Mazurier1,2, P. Dubus2,4,5, G. Belleannée6, D. Collet6, I. Soubeyran6,  
S. Evrard6, N. Senant-Dugot7, F. Mégraud1,2, C. Varon1,2;  
1INSERM U853, Bordeaux, France, 2Université de Bordeaux, Bordeaux, France, 3INSERM U1035, Bordeaux, France, 4EA 2406, Bordeaux, France, 5CHU Bordeaux, Bordeaux, France, 6Institut Bergonié, Bordeaux, France, 7SFR TransBioMed, Bordeaux, France.

**W5.6** The role of PTEN/FAK signaling pathways in the pathogenesis of *Helicobacter pylori*-associated gastric cancer  
X. Cao, Z. Yang, N. Lu; Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
11.00 – 12.30 hrs Workshop 6. Extradigestive and Others

Room: Sala Italia

Chair: V. Mahachai, Thailand
F. Di Mario, Italy

Speaking time: 12’+3’

W6.1 Does *Helicobacter pylori* infection impact the course of Alzheimer’s disease? An animal study

C. Roubaud-Baudron1,2,3, L. Blaszczzyk2,4, C. Varon1,2, L. Chambonnier1,2, A. Giese2,5, P. Dubus2,6, N. Macrez2,6, S. Pietropaolo2,7, T. Leste-Lasserre3,4, P. Costet3,5, B. Rousseau2,5, V. Fenelon2,4, Y. Cho2,1, F. Mégraud1,2, N. Salles1,2,3; 1INSERM U853, Bordeaux, France, 2Université de Bordeaux, Laboratoire de Bactériologie, Bordeaux, France, 3Pôle de gérontologie clinique, CHU de Bordeaux, Bordeaux, France, 4INSERM U862, Bordeaux, France, 5EA 2406, Bordeaux, France, 6CNRS, UMR 5293, Bordeaux, France, 7CNRS, UMR 5287, Bordeaux, France, 8Animalerie spécialisée, Bordeaux, France, 9Animalerie A2, Bordeaux, France.

W6.2 Diversity of the gastric microbiota in *H. suis*-infected and *H. suis*-negative slaughterhouse pigs

E. De Bruyne1, B. Taminiau2, F. Pasmans1, A. Smet1, C. De Witte1, G. Daube2, V. Delcenserie2, R. Ducatelle1, F. Haesebrouck1, B. Flahou1; 1Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 2Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.

W6.3 Serological Association of *Helicobacter pylori* proteins and biliary tract cancer in the ATBC study

G. Murphy1, A. Michel1, P. R. Taylor1, D. Albanes1, S. J. Weinstein1, J. Virtamo2, D. Parisi3, K. Snyder4, J. Butt5, K. A. McGlynn1, J. Koshiol1, M. Pawlita2, G. Y. Lai1, C. C. Abnet1, S. M. Dawsey1, N. D. Freedman1; 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, 2Research Program Infection and Cancer (F020), German Cancer Research Center (DKFZ), Heidelberg, Germany, 3Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland, 4Information Management Services, Inc., Rockville, MD, United States.

W6.4 Influence of gastrointestinal microbiota on pathogenic potential of *Helicobacter pylori* in C57BL/6 mice

Z. Ge, Y. Feng, A. Sheh, S. Muthupalani, C. Wang, J. G. Fox; Massachusetts Institute of Technology, Cambridge, MA, United States.

W6.5 *Helicobacter pylori* and preeclampsia: role of anti-CagA antibodies on placental development

N. Di Simone1, C. Tersigni1, F. Di Nicuolo1, R. Castellani1, F. Bugli2, A. Gasbarrini2, G. Scambia1, F. Francesch1; 1Department of Obstetrics and Gynecology, Policlinico A. Gemelli, Università Cattolica Del Sacro Cuore, Rome, Italy, 2Institute of Microbiology, Policlinico A. Gemelli, Università Cattolica Del Sacro Cuore, Rome, Italy, 3Department of Internal Medicine, Policlinico A. Gemelli, Università Cattolica Del Sacro Cuore, Rome, Italy, 4Emergency Department, Policlinico A. Gemelli, Università Cattolica Del Sacro Cuore, Rome, Italy.

W6.6 Semen levels of interleukin-6 and tumour necrosis factor-α are increased in CagA positive *H. pylori* infection and may cause sperm alterations

E. Moretti1, G. Collodel2, M. Campagna2, S. Gonnelli2, F. Iacoponi2, N. Figura2; 1Dept. of of Molecular and Developmental Medicine, University of Siena, Siena, Italy, 2Dept. of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Italy.
12.30 – 13.30 hrs  
**Industry-Sponsored Satellite Symposium - See page 25 for more information**  
*Room: Auditorium*

13.30 – 14.30 hrs  
**Poster Rounds & Lunch**  

The following posters will be discussed with the authors:

**Group 3:**
- 4. Epidemiology and transmission
- 9. Paediatric issues
- 10. Diagnosis

*Chairs:
P04.01 - P04.19:  R. Herrero, France  
M. Zagari, Italy

P09.17 - P09.08:  P. de Angelis, Italy  
P. Valentini, Italy

P10.32 - P10.32:  Y. Niv, Israel  
L. Andersen, Denmark

**Group 4:**
- 5. Inflammation and host response
- 6. Pathology and pathophysiology
- 7. Preneoplastic and neoplastic diseases

*Chairs:
P05.01 - P05.12:  A. Ristimäki, Finland  
F. Bonvicini, Italy

P06.01 - P06.05:  A. Ristimäki, Finland  
F. Bonvicini, Italy

P07.01 - P07.19:  V. Mahachai, Thailand  
A. Sgambato, Italy

**Group 5:**
- **18. H. pylori and Gastric Cancer**

*Chairs:
P18.01 - P18.16:  P. Moayeddi, Canada  
M. Romano, Italy

P18.17 - P18.31:  M. Leja, Latvia  
M. Caselli, Italy

**Group 6:**
- 8. Oesophageal and extradigestive diseases
- 12. NSAIDs, COXIBs, ASA and *H. pylori* infection
- 16. Other Helicobacters
- 17. Hepatobiliary Diseases

*Chairs:
P08.01 - P08.12 &  B. Annibale, Italy
P12.01 - P12.02 &  M. Candelli, Italy
P14.01 - P14.03 &
P16.01 - P16.08 &
P17.01 - P17.02:
PROGRAMME SATURDAY, SEPTEMBER 13

14.30 – 16.00 hrs  
Symposium: Prevention of gastric cancer by \textit{H. pylori} eradication

\textit{Auditorium}

Chair: A. Axon, United Kingdom  
G. Nardone, Italy

Speaking Time: 17’+3’

\textit{Report of the IARC Working Group Meeting on H. pylori eradication for gastric cancer prevention}
Rolando Herrero, Lyon, France

\textit{Cost-effectiveness of test and treat strategy for gastric cancer prevention}
Paul Moayeddi, Hamilton, ON, Canada

\textit{Prevention of gastric cancer besides H. pylori eradication in Korea}
Soo Heon Park, Seoul, Korea

\textit{Public health perspectives}
Ruggero de Maria, Rome, Italy

16.00 – 16.30 hrs  
Coffee break

16.30 – 18.00 hrs  
Symposium: Best \textit{H. pylori} eradicating schemes

\textit{Auditorium}

Chair: K. Sugano, Japan  
F. Bazzoli, Italy

Speaking Time: 17’+3’

\textit{Back to the future: Bismuth}
David Graham, Houston, TX, USA

\textit{Non-bismuth quadruple therapies}
Javier P. Gisbert, Madrid, Spain

\textit{Personalised treatment}
Takahisa Furuta, Hamamatsu, Japan

\textit{Back from the future: Vaccine}
Antonello Covacci, Siena, Italy

18.00 – 18.30 hrs  
Closing Session

\textit{Auditorium}

Chair: G. Gasbarrini, Italy  
F. Mégraud, France

\textit{Awarding of the Marshall & Warren Medal to Manfred Kist, Freiburg, Germany}

\textit{Presentation of the EHSG Presentation and Poster Awards}

\textit{Presentation of the next meeting in Nicosia (G. Potamitis)}

\textit{Closing remarks}
SCIENTIFIC INFORMATION, POSTER SCHEDULE

Poster Presentations

ATTENTION: Posters are on display for one day only. Posters need to be taken off by the author at the end of the day. Posters not removed until then will be removed by the staff. Posters will be discarded, and neither kept nor sent to the authors. Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of one of the authors is mandatory during the following times:

Friday, September 12, 2014, 13.30 – 14.30 hrs

Group 1:  P01. Microbiology,  
P02. Molecular Genetics and Genomics  
P03. Virulence Factors and Pathogenesis  
P13. Drug Resistance

Group 2:  P11. Clinical trials and novel treatments  
P15. Probiotics

Mounting of the posters in Rounds 1 & 2 is possible on Friday, September 12, 2014 from 8.00 hrs  
Removal on Friday, September 12, 2014, from 16.30 hrs.

Saturday, September 13, 2014, 13.30 – 14.30 hrs

Group 3:  P04. Epidemiology and transmission  
P09. Paediatric issues  
P10. Diagnosis  
P11. Clinical Trials and Novel Treatments

Group 4:  P05. Inflammation and host response  
P06. Pathology and pathophysiology  
P07. Preneoplastic and neoplastic diseases

Group 5:  P18. H. pylori and Gastric Cancer

Group 6:  P08. Oesophageal and extradigestive diseases  
P12. NSAIDs, COXIBs, ASA and H. pylori infection  
P16. Other Helicobacters  
P17. Hepatobiliary Diseases

Mounting of the posters in Rounds 3-6 is possible on Saturday, September 13, 2014 from 8.00 hrs  
Removal on Saturday, September 13, 2014, from 15.30 hrs.

Format
The usable surface on the poster board is 90 cm width x 150 cm height (portrait format). Adhesive material will be made available.
Oral Presentations

Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to your presentation. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion. Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical Setting
All rooms are equipped with a (Windows) PC and data projector for Power Point presentation only.

Handing in Your Presentation:
It must then be handed over to the technician of the according lecture room in a break at least 1 hour before your talk either via USB-Memory Stick or CD-Rom (30 minutes for talks in the first morning sessions).

Presentation Format - Technical Issues:
The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Please bring a USB drive, formatted for Windows® (PC). You may want to carry a second USB-memory drive as a back-up in case there is any technical problem.
File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows 7®). Maximum Resolution: XGA (1024 x 768 pixel)
Friday, September 12, 2014
12:30 - 13:30 hrs  SANOFI Satellite Symposium: Role of *Bacillus clausii* in antibiotic-associated gastrointestinal side effects

Chair:  G. Daoud, Venezuela

*Interactions between probiotics and* *H. pylori*
*Antonio Gasbarrini (15 min)*

*Antibiotic-associated diarrhea and the role of* *B. clausii* *as adjuvants in the treatment of* *H. pylori*
*Ana Tereza Abreu Y Abreu (15 min)*

*B. clausii* *in children with* *H. pylori* *infection*
*Georgette Daoud (15 min)*

Discussion (15 min)

Saturday, September 13, 2014
12:30 - 13:30 hrs  ALMIRALL Satellite Symposium

Chair:  A. Gasbarrini, Italy

*Abdominal Pain, Bloating and Constipation in IBS-C: three symptoms, one therapy*
*Matteo Neri (30 minutes)*

Discussion (30 minutes)

SPONSORS

As per printing date

The organisers gratefully acknowledge the support of the following institutions and companies:

- AG Pharma Srl
- Almirall SpA
- INFAI GmbH
- ITALCHIMICI SpA
- Sanofi Aventis Group
- Sanofi LatAM
- Sofar SpA

LIST OF EXHIBITORS

As per printing date

- Aptalis Pharma SAS
- Biohit Oyi, Helsinki, SWE
- Delta Analytics OHG
- Fischer AAnalysen Instrumente GmbH
- Meridian Bioscience Europe
- Trinity Biotec

www.helicobacter.org
GENERAL INFORMATION

In alphabetical order.

Badges
Participants should collect name badges from the conference registration desks. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Banks
Traditional Bank business hours are from Monday to Friday, 08.20-13.30 hrs. Banks are usually closed on Saturday and Sunday. All bank agency have ATMs outside to provide 24-hours service. The local currency (Euro) can also be obtained from banks and exchange bureaus.

Cancellations and Refunds
Notice of cancellation had to be made in writing by email or fax to the Congress Office. The policy for refunding registration fees is as follows:
- Written cancellation received:
  - Before August 15, 2014: 75% refund
  - After August 15, 2014: no refund
The date of the email or fax ID is the basis for considering refunds. Refunds will be made after the congress.

Certificate of Attendance
Confirmations of attendance will be issued at the registration desk.

CME Credits
The “International Workshop on Helicobacter & Microbiota in Inflammation & Cancer” was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Coffee Breaks and Lunch
During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges. Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Price per day: EUR 10.-. Lunch tickets are not refundable.

Congress Venue
Sacred Heart Catholic University (Universita' Cattolica del Sacro Cuore)
'Europa' Congress Center
Largo Francesco Vito, 1
00168 Rome, Italy

How to reach the venue
Line A underground, direction Battistini and get off at “Valle Aurelia-Cornelia”.
From there:
- take the FM3 line train “Roma-Viterbo” and get off at “Gemelli” or
- go up to the bus stop and take one of the following buses:
  - n. 994 (direction Valle Aurelia - Pineta Sacchetti, Ospedale San Filippo Neri)
  - n. 446 (direction Circonvallazione Cornelia - Pineta Sacchetti - Cortina d’Ampezzo - Ponte Milvio - Piazza Mancini)
  - n. 146 (direction Battistini - Pineta Sacchetti - Policlinico Gemelli)
Get off at “Pineta Sacchetti/Acqua Paola”

Currency
The official currency of Spain is the Euro (EUR).
1 EUR = 1,32 USD = 0,80 GBP = 137 JPY = 1,21 CHF = 9,17 SEK = 7,45 DKK = 1,41 AUD
as per date of printing.

Electricity Supply
220-240 V - 50Hz AC, using CEI 23-50, CEI 23-5, some (older) sockets will not accept CEE 7/7 plugs, however in modern installations multiple standard sockets have been used.

GSM cell phone roaming
GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire at your provider which roaming company in Italy offers the cheapest tariffs.

Internet
You will find Internet cafés throughout the city. WIFI is available, please ask for a code at the registration desk.

Language
The official language of the congress is English (no simultaneous translation).
GENERAL INFORMATION

Liability
In registering for the EHSG 2014 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the registration desk at the Congress Centre
Thursday, September 11, 2014:  13.00 – 17.30 hrs
Friday, September 12, 2014:  08.00 – 18.00 hrs
Saturday, September 13, 2014:  08.00 – 18.00 hrs

Poster Removal
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept nor mailed to the author after the meeting.

Presentations
All presenters should hand in their electronic presentation to the technician of the according lecture room in a break at least 1 hour before your talk either via USB-Memory drive (30 minutes for talks in the first morning sessions).

Restaurants
Italian cuisine is one of the most glamorous in the world. Italian restaurants also offer a wide range of dishes which may be “typically” Italian or authentic regional cuisine. Italy is the place where antiquity perfectly merges with the modern. It is composed of many regions and each one of them has unique traditions and cuisine.

The notion that Italian food essentially means Pizza, Pasta, Macaroni, Spaghetti or Meat balls is wrong, there is so much more to satisfy your appetite.

Safety - Crime
Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern.

Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Shopping
The opening hours of most shops in Rome are 10.00-19.00 hrs from Monday to Saturday. Some of them are open also on Sundays.

Smoking Policy
The EHSG 2014 Workshop is a “No-smoking-Conference”. Smoking is banned from all public buildings, bars and restaurants in Italy.

Staff
If you should have any questions, the congress staff will be pleased to help you.

Taxi
Taxis are white or yellow, with an identification name and number on the front door and a taximeter inside. You find them in taxi parkings or by calling a radiotaxi.

Here are some numbers of taxi companies: +39-06/3570; +39-06/6645; +39-06/822; +39-06/157; +39-06/4994; +39-06/5551.

Weather
September in Rome
- Average high:  21°C / 70°F
- Average low:  15°C / 59°F
- Average rainfall:  68 mm / 2 1/2 in

The weather continues to cool down in Rome in September, although the city is still pleasantly warm. At the beginning of the month, the average temperature starts off at 23°C and slowly drops until it reaches 19°C in the final few days of the month. In September, Rome experiences ten hours of sunshine each day and a pleasantly warm average sea temperature of 24°C toward the coast. With around 68mm of rainfall spread across nine days, there is a small chance you’ll experience a shower or two. (Source: www.holiday-weather.com)
### Registration Fees

<table>
<thead>
<tr>
<th>Payment received</th>
<th>Before July 15, 2014</th>
<th>After July 15, 2014 and on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Participants</td>
<td>EUR 300.–</td>
<td>EUR 400.–</td>
</tr>
<tr>
<td>Young Scientists (&lt;35 years)</td>
<td>EUR 150.–</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Students (&lt; 30 years)</td>
<td>EUR 100.–</td>
<td>EUR 100.–</td>
</tr>
<tr>
<td>Company Representatives</td>
<td>EUR 450.–</td>
<td>EUR 550.–</td>
</tr>
<tr>
<td>Combined Fee EHSG &amp; EAGEN Regular Participants</td>
<td>EUR 400.–</td>
<td>EUR 500.–</td>
</tr>
<tr>
<td>Combined Fee EHSG &amp; EAGEN Young Scientists &lt;35</td>
<td>EUR 250.–</td>
<td>EUR 300.–</td>
</tr>
<tr>
<td>Day Ticket</td>
<td>-</td>
<td>EUR 200.–</td>
</tr>
<tr>
<td>Networking Evening</td>
<td>Fully booked</td>
<td>Fully booked</td>
</tr>
</tbody>
</table>

**Payment of Registration fees** may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

**Please note**
The reduced registration fee was only applicable, *if it has been credited to the congress account before the deadline*. Registering before July 15, 2014 without performing an actual payment was not sufficient to benefit from the reduction.

**What is covered by the registration fee?**
- Admission to all scientific sessions and the exhibition
- Admission to the networking mixer
- Programme
- 1 copy of “Year in Helicobacter 2014” & the abstract book
- Refreshments during coffee breaks

**Cancellations**
Notice of cancellation must have been made in writing by email or fax to the Congress Office. The date of the email/fax ID was the basis for considering refunds.
Registration fees may be refunded after the workshop as follows:
- Cancellation received before August 15, 2014: 75% refund
- after August 15, 2014: no refund

### Networking Events

**Thursday, September 11, 2014, 17.30 hrs**
Networking Mixer at the Catholic University, Atrio Polonia, or outside, weather permitting.

**Friday, September 12, 2014, 20.00 hrs**
EHSG Networking Evening in the Checco Er Carettiere - The Event is fully booked!
Price: EUR 50.–
Ticket is required and will be checked at the entrance.